A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor α agonists.

GW7647 PPARα agonist drug delivery fatty acid–binding protein nuclear magnetic resonance (NMR) nuclear receptor peroxisome proliferator-activated receptor (PPAR) protein structure transcription factor

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
08 03 2019
Historique:
received: 26 11 2018
revised: 17 12 2018
pmc-release: 08 03 2020
pubmed: 2 1 2019
medline: 21 5 2019
entrez: 2 1 2019
Statut: ppublish

Résumé

Peroxisome proliferator-activated receptor α (PPARα) is a transcriptional regulator of lipid metabolism. GW7647 is a potent PPARα agonist that must reach the nucleus to activate this receptor. In cells expressing human fatty acid-binding protein 1 (FABP1), GW7647 treatment increases FABP1's nuclear localization and potentiates GW7647-mediated PPARα activation; GW7647 is less effective in cells that do not express FABP1. To elucidate the underlying mechanism, here we substituted residues in FABP1 known to dictate lipid signaling by other intracellular lipid-binding proteins. Substitutions of Lys-20 and Lys-31 to Ala in the FABP1 helical cap affected neither its nuclear localization nor PPARα activation. In contrast, Ala substitution of Lys-57, Glu-77, and Lys-96, located in the loops adjacent to the ligand-binding portal region, abolished both FABP1 nuclear localization and GW7647-induced PPARα activation but had little effect on GW7647-FABP1 binding affinity. Using solution NMR spectroscopy, we determined the WT FABP1 structure and analyzed the dynamics in the apo and GW7647-bound structures of both the WT and the K57A/E77A/K96A triple mutant. We found that GW7647 binding causes little change in the FABP1 backbone, but solvent exposes several residues in the loops around the portal region, including Lys-57, Glu-77, and Lys-96. These residues also become more solvent-exposed upon binding of FABP1 with the endogenous PPARα agonist oleic acid. Together with previous observations, our findings suggest that GW7647 binding stabilizes a FABP1 conformation that promotes its interaction with PPARα. We conclude that full PPARα agonist activity of GW7647 requires FABP1-dependent transport and nuclear localization processes.

Identifiants

pubmed: 30598509
pii: S0021-9258(20)38995-X
doi: 10.1074/jbc.RA118.006848
pmc: PMC6416440
doi:

Substances chimiques

Butyrates 0
FABP1 protein, human 0
Fatty Acid-Binding Proteins 0
GW 7647 0
Ligands 0
PPAR alpha 0
Phenylurea Compounds 0

Banques de données

PDB
['2L67', '3STN', '2F73', '2L68', '6DO6', '6DO7', '6DRG']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3720-3734

Informations de copyright

© 2019 Patil et al.

Références

J Biomol NMR. 1994 Sep;4(5):603-14
pubmed: 22911360
J Mol Biol. 2007 Oct 5;372(5):1246-60
pubmed: 17761196
J Biomol NMR. 2009 Aug;44(4):213-23
pubmed: 19548092
Biochemistry. 2007 Jun 12;46(23):6744-52
pubmed: 17516629
FEBS J. 2014 May;281(9):2266-83
pubmed: 24628888
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2323-8
pubmed: 11226238
Cell. 2007 May 18;129(4):723-33
pubmed: 17512406
J Mol Biol. 2001 Jan 26;305(4):939-49
pubmed: 11162104
J Appl Genet. 2006;47(1):39-48
pubmed: 16424607
J Biomol NMR. 1998 Feb;11(2):221-6
pubmed: 9679296
J Mol Biol. 2002 May 24;319(1):209-27
pubmed: 12051947
J Magn Reson. 2011 Dec;213(2):423-41
pubmed: 22152361
Biochemistry. 2011 Mar 1;50(8):1283-95
pubmed: 21226535
Mol Cell Biol. 2002 Jul;22(14):5114-27
pubmed: 12077340
Mol Cell. 2005 Apr 29;18(3):343-53
pubmed: 15866176
Experientia. 1990 Jun 15;46(6):617-30
pubmed: 2193826
J Biol Chem. 2015 May 29;290(22):13895-906
pubmed: 25847235
J Mol Biol. 1997 Oct 17;273(1):283-98
pubmed: 9367762
ACS Chem Biol. 2014 Nov 21;9(11):2526-34
pubmed: 25144524
Prog Nucl Magn Reson Spectrosc. 2011 Oct;59(3):271-92
pubmed: 21920222
J Mol Graph. 1996 Feb;14(1):51-5, 29-32
pubmed: 8744573
J Biol Chem. 2011 Sep 9;286(36):31924-8
pubmed: 21757748
J Biol Chem. 1999 Aug 20;274(34):23695-8
pubmed: 10446126
J Biol Chem. 2014 May 23;289(21):14941-54
pubmed: 24692551
J Biomol NMR. 1995 Nov;6(3):277-93
pubmed: 8520220
J Biol Chem. 1997 Mar 14;272(11):7140-50
pubmed: 9054409
J Med Chem. 2008 Jul 10;51(13):3755-64
pubmed: 18533710
Biophys J. 2012 Jun 6;102(11):2585-94
pubmed: 22713574
J Biomol NMR. 2008 Jul;41(3):127-38
pubmed: 18512031
Int J Biochem Cell Biol. 2001 Sep;33(9):865-76
pubmed: 11461829
J Biomol NMR. 2008 Sep;42(1):23-33
pubmed: 18709333
J Biomol NMR. 1994 Mar;4(2):171-80
pubmed: 8019132
Biochim Biophys Acta Proteins Proteom. 2017 Sep;1865(9):1152-1159
pubmed: 28668637
J Biomol NMR. 2002 Nov;24(3):171-89
pubmed: 12522306
Biochemistry. 1997 Feb 11;36(6):1450-60
pubmed: 9063893
Chem Biol. 2007 Apr;14(4):453-65
pubmed: 17462580

Auteurs

Rahul Patil (R)

From Medicinal Chemistry.

Bonan Liu (B)

Drug Delivery, Disposition and Dynamics, and.

Indu R Chandrashekaran (IR)

From Medicinal Chemistry.

Stephen J Headey (SJ)

From Medicinal Chemistry.

Martin L Williams (ML)

From Medicinal Chemistry.

Craig S Clements (CS)

From Medicinal Chemistry.

Olga Ilyichova (O)

From Medicinal Chemistry.

Bradley C Doak (BC)

From Medicinal Chemistry.

Patrick Genissel (P)

the Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France.

Richard J Weaver (RJ)

the Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France.

Laurent Vuillard (L)

the Institut de Recherches Servier, 125 Chemin de Ronde, 78290 Croissy-sur-Seine, France.

Michelle L Halls (ML)

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia and michelle.halls@monash.edu.

Christopher J H Porter (CJH)

Drug Delivery, Disposition and Dynamics, and chris.porter@monash.edu.

Martin J Scanlon (MJ)

From Medicinal Chemistry, martin.scanlon@monash.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH